Polycythemia vera (PV), a myeloproliferative neoplasm characterized by an increase in red blood cell (RBC) mass, is classified under the International Classification of Diseases, 10th Revision (ICD-10) code D45.0. Understanding this code is crucial for proper diagnosis, treatment, and reimbursement.
D45.0 Polycythemia vera
* Subcategory: Myeloproliferative neoplasms
D45.1 Polycythemia vera with myelofibrosis
* Subcategory: Myeloproliferative neoplasms
D45.2 Idiopathic polycythemia vera
D45.8 Other polycythemias
* Subcategory: Polycythemia
According to the American Cancer Society, PV affects approximately 4.5 people per 100,000, with a higher incidence in males than females. The median age at diagnosis is around 60 years.
PV is characterized by an increase in RBC mass, leading to elevated hematocrit and hemoglobin levels. Other clinical features include:
ICD-10 codes facilitate accurate diagnosis of PV, guided by the following criteria:
The primary goal of PV treatment is to reduce the risk of thromboembolism and other complications. Treatment options include:
Accurate ICD-10 coding is essential for proper reimbursement and quality of care. The following guidelines should be followed:
2024-11-17 01:53:44 UTC
2024-11-18 01:53:44 UTC
2024-11-19 01:53:51 UTC
2024-08-01 02:38:21 UTC
2024-07-18 07:41:36 UTC
2024-12-23 02:02:18 UTC
2024-11-16 01:53:42 UTC
2024-12-22 02:02:12 UTC
2024-12-20 02:02:07 UTC
2024-11-20 01:53:51 UTC
2024-07-16 22:15:20 UTC
2024-07-16 22:15:21 UTC
2024-07-16 22:29:48 UTC
2024-07-16 22:29:48 UTC
2024-07-27 21:36:57 UTC
2024-07-27 21:37:06 UTC
2025-01-04 06:15:36 UTC
2025-01-04 06:15:36 UTC
2025-01-04 06:15:36 UTC
2025-01-04 06:15:32 UTC
2025-01-04 06:15:32 UTC
2025-01-04 06:15:31 UTC
2025-01-04 06:15:28 UTC
2025-01-04 06:15:28 UTC